Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An international Overall Survival clinical study with the combination of Ceplene and low dose Proleukin.

Trial Profile

An international Overall Survival clinical study with the combination of Ceplene and low dose Proleukin.

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 21 Feb 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aldesleukin (Primary) ; Histamine dihydrochloride (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms REMAIN
  • Most Recent Events

    • 17 Feb 2017 According to an Immune Pharmaceuticals media release, company will announce the launch of this trial at the Acute Leukemia XVI symposium 2017. Patient recruitment is expected to start in later 2017.
    • 22 Nov 2016 According to an Immune Pharmaceuticals media release, following the guidance from the Food and Drug Administration, the Ceplene Scientific Advisory Board (SAB) will review the proposed clinical protocol of this study.
    • 27 Oct 2016 According to an Immune Pharmaceuticals media release, company has received guidance from the United States Food and Drug Administration (FDA) on this study. FDA reviewed the study design and provided feedback relating to specific design elements. Company plans to submit the final protocol for the phase III study in early 2017.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top